Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients

Summary

The aim is to demonstrate a decrease in complications among ambulatory patients who are diagnosed with mild COVID-19 by treating them with nitazoxanide for 7 to 14 days on top of standard care compared to patients who receive standard care and placebo only.

Timeline

Start

2020-07

Primary completion

2020-09

Completion

2020-09

Outcome

Outcome not reported

Stopped (Business): “Sponsor's strategic decision”

Drugs

Indications